Navigation Links
Metamark Genetics, Inc. Announces New Chief Scientific Officer
Date:9/16/2010

CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Metamark Genetics, Inc., a privately held molecular diagnostics company developing innovative personalized medicine approaches to optimize cancer care, announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. as Chief Scientific Officer.

Dr. Blume-Jensen joins Metamark with over 20 years of experience in cancer research and oncology drug discovery. From 2001 to 2008 Dr. Blume-Jensen was department head at EMD Serono, Inc. and later at Merck Research Laboratories, Merck & Co, Inc. where he established integrated oncology R&D programs linking therapeutics to patient responder populations. During his tenure he advanced a number of pre-clinical drug programs into the clinic, and provided translational support for clinical programs. Since 2008 he served as Exec. Dir., External Scientific Affairs and Vice President of Daiichi Sankyo Research Institute, Daiichi Sankyo Inc., was 'Therapeutic Area Advisor' for Oncology, and helped formulate a global oncology R&D strategy. Dr. Blume-Jensen's pioneering work on oncogenic signaling, disease mouse models, and more recently efficacy-predictive biomarkers for oncology therapeutics is highly cited. Dr. Blume-Jensen obtained his M.D. from Copenhagen, Denmark, his Ph.D. from Dr. Carl-Henrik Heldin's laboratory at the Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral studies in Dr. Tony Hunter's laboratory at the Salk Institute, La Jolla, CA.

Kenneth E. Weg, Metamark's Chairman and CEO stated, "Metamark is very fortunate to have attracted a true leader in the personalized oncology movement to shepherd Metamark's ambitious Research and Development efforts. We welcome Dr. Blume-Jensen to the expanding Metamark team."

Dr. Blume-Jensen stated, "I am very excited about the innovative, function-driven Metamark platform and the opportunity to join the Metamark team to help catapult the launch of the first MetamarkDx™ Prognostic Assays. I am looking forward to applying my expertise in personalized oncology medicine and predictive biomarkers to help transform Metamark into the leading next generation molecular diagnostics company."

Cautionary Note Regarding Forward-Looking Statements

This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results, are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.   Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.  


'/>"/>
SOURCE Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
2. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
3. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Anesiva Announces Second Quarter 2008 Financial Results and Update
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... , ... In starting a program to hire college athletes, Catalyst ... for skill.” , In keeping with this philosophy, the Catalyst an Iowa premix manufacturer ... hoping to replicate the practice throughout the company. , “I’ve heard coaches talk on ...
(Date:2/26/2017)... ... 2017 , ... Rob Lowe is a well recognized television personality, so it ... on issues that are important to the American public and important to society at ... a hot topic around the world for a few years. , The climate and ...
(Date:2/24/2017)... ... February 24, 2017 , ... A study recently ... in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, when ... studies. , Jake Lubinski, president of AxioMed, commented on the recent publication, ...
(Date:2/24/2017)... ... February 24, 2017 , ... Chef Jodi Abel has returned from her ... several cities, she gained a number of delicious recipes and new techniques to share ... South Africa’s Western Cape province. It is internationally renowned for its incredible wine ...
Breaking Biology Technology:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/1/2017)... BOSTON, Massachusetts , February 1, 2017 ... and events on emerging technology, announces the availability of a new ... Continue Reading ... ... systems in industrial and collaborative robots. Source: IDTechEx Report "Sensors for ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):